|
US2811483A
(en)
*
|
1954-12-09 |
1957-10-29 |
Pfizer & Co C |
Pharmaceutical composition and process for preparing the same
|
|
DE1091289B
(de)
*
|
1956-01-25 |
1960-10-20 |
Hans Lowey |
Verfahren zur Herstellung einer oral anzuwendenden Arzneiform mit verlaengerter Wirkungsdauer
|
|
US2921001A
(en)
*
|
1957-04-16 |
1960-01-12 |
Sterling Drug Inc |
Multi-layered pill or tablet with indicating lamination
|
|
NL235736A
(cg-RX-API-DMAC7.html)
*
|
1958-02-03 |
|
|
|
|
GB906422A
(en)
*
|
1958-05-02 |
1962-09-19 |
Wellcome Found |
Improvements in and relating to prolonged acting pharmaceutical preparations
|
|
US3131123A
(en)
*
|
1959-03-13 |
1964-04-28 |
Lab Francais De Therapeutique |
Enteric tablets and manufacture thereof
|
|
US3181998A
(en)
*
|
1960-08-12 |
1965-05-04 |
Joseph L Kanig |
Tablet disintegration
|
|
US3147187A
(en)
*
|
1962-09-10 |
1964-09-01 |
Don Hall Lab |
Sustained release pharmaceutical
|
|
US5019302A
(en)
*
|
1986-03-12 |
1991-05-28 |
Washington University Technology Associates, Inc. |
Method for granulation
|
|
US6632429B1
(en)
|
1999-12-17 |
2003-10-14 |
Joan M. Fallon |
Methods for treating pervasive development disorders
|
|
US20070053895A1
(en)
|
2000-08-14 |
2007-03-08 |
Fallon Joan M |
Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
|
|
US8030002B2
(en)
|
2000-11-16 |
2011-10-04 |
Curemark Llc |
Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
US9320780B2
(en)
|
2008-06-26 |
2016-04-26 |
Curemark Llc |
Methods and compositions for the treatment of symptoms of Williams Syndrome
|
|
PL2318035T3
(pl)
|
2008-07-01 |
2019-10-31 |
Curemark Llc |
Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
|
|
US10776453B2
(en)
|
2008-08-04 |
2020-09-15 |
Galenagen, Llc |
Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
|
|
US20100092447A1
(en)
|
2008-10-03 |
2010-04-15 |
Fallon Joan M |
Methods and compositions for the treatment of symptoms of prion diseases
|
|
CA2747703C
(en)
|
2009-01-06 |
2021-06-15 |
Curemark Llc |
Compositions and methods for the treatment or the prevention of infections by e. coli
|
|
JP5684725B2
(ja)
|
2009-01-06 |
2015-03-18 |
キュレロン リミテッド ライアビリティ カンパニー |
黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
US9511125B2
(en)
|
2009-10-21 |
2016-12-06 |
Curemark Llc |
Methods and compositions for the treatment of influenza
|
|
CA2838801C
(en)
*
|
2010-06-15 |
2019-06-04 |
University Of South Florida |
A method of modulated exothermic chemical systems through phase change materials
|
|
GB2497715A
(en)
*
|
2010-11-19 |
2013-06-19 |
Curemark Llc |
Preparation and use of combination enzyme and gastriontestinal modulator delivery systems
|
|
DK2701733T3
(da)
|
2011-04-21 |
2019-05-27 |
Curemark Llc |
Forbindelser til behandling af neuropsykiatriske forstyrrelser
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
WO2018191233A1
(en)
|
2017-04-10 |
2018-10-18 |
Curemark, Llc |
Compositions for treating addiction
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|